News

News Subscription

Feb 24. 2021
Basilea successfully placed 1 million new registered shares, raising gross proceeds of CHF 45.75 million
Read more Download
Feb 23. 2021
Basilea launches a private placement of new shares by way of an accelerated bookbuilding
Read more Download
Feb 16. 2021
Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets
Read more
Download
Feb 15. 2021
Basilea announces divestment of its Chinese R&D subsidiary to PHT International
Read more
Download
Feb 12. 2021
Basilea reports derazantinib/PD-L1 checkpoint inhibitor combination results from dose-finding part of FIDES-02 study in patients with solid tumors at ASCO GU symposium
Read more
Download
Feb 11. 2021
Basilea achieves preclinical milestone in oncology collaboration on potential first-in-class kinase inhibitor
Read more
Download
Feb 10. 2021
Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer (iCCA)
Read more
Download
Feb 09. 2021
Continued strong Cresemba® (isavuconazole) sales trigger milestone from Pfizer to Basilea of USD 10 million
Read more
Download
Jan 11. 2021
Basilea reports preliminary 2020 revenue and portfolio progress
Read more
Download
Jan 07. 2021
Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal isavuconazole (Cresemba®) in Japan
Read more
Download